184 related articles for article (PubMed ID: 3307402)
21. Achieving therapeutic goals in insulin-using diabetic patients with non-insulin-dependent diabetes mellitus. A weight reduction-exercise-oral agent approach.
Lucas CP; Patton S; Stepke T; Kinhal V; Darga LL; Carroll-Michals L; Spafford TR; Kasim S
Am J Med; 1987 Sep; 83(3A):3-9. PubMed ID: 3307404
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.
Berelowitz M; Fischette C; Cefalu W; Schade DS; Sutfin T; Kourides IA
Diabetes Care; 1994 Dec; 17(12):1460-4. PubMed ID: 7882817
[TBL] [Abstract][Full Text] [Related]
23. Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus.
Kilo C; Meenan A; Bloomgarden Z
Clin Ther; 1992; 14(6):801-12. PubMed ID: 1286487
[TBL] [Abstract][Full Text] [Related]
24. Multicenter comparison of glyburide and glipizide in the treatment of non-insulin-dependent diabetes mellitus.
Kilo C
Clin Ther; 1988; 10(3):294-302. PubMed ID: 3152586
[TBL] [Abstract][Full Text] [Related]
25. Effect of glipizide treatment on various aspects of glucose, insulin, and lipid metabolism in patients with noninsulin-dependent diabetes mellitus.
Reaven GM
Am J Med; 1983 Nov; 75(5B):8-14. PubMed ID: 6369970
[TBL] [Abstract][Full Text] [Related]
26. Benefits and risks with glyburide and glipizide in elderly NIDDM patients.
Brodows RG
Diabetes Care; 1992 Jan; 15(1):75-80. PubMed ID: 1737544
[TBL] [Abstract][Full Text] [Related]
27. Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.
Emanuele N; Klein R; Abraira C; Colwell J; Comstock J; Henderson WG; Levin S; Nuttall F; Sawin C; Silbert C; Lee HS; Johnson-Nagel N
Diabetes Care; 1996 Dec; 19(12):1375-81. PubMed ID: 8941467
[TBL] [Abstract][Full Text] [Related]
28. Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide.
Lev JD; Zeidler A; Kumar D
Diabetes Care; 1987; 10(6):679-82. PubMed ID: 3123183
[TBL] [Abstract][Full Text] [Related]
29. Effect of bed time intermediate acting insulin in NIDDM subjects refractory to a combination of sulphonylureas and biguanides.
Seshiah V; Shanker R; Madhavan R; Venkataraman S; Sundaram A; Seshasaianam C; Sankaran JR
J Assoc Physicians India; 1992 Oct; 40(10):666-8. PubMed ID: 1307353
[TBL] [Abstract][Full Text] [Related]
30. Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
Skoff RA; Waterbury NV; Shaw RF; Egge JA; Cantrell M
J Manag Care Pharm; 2011 Nov; 17(9):664-71. PubMed ID: 22050391
[TBL] [Abstract][Full Text] [Related]
31. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance.
Levy J; Vandenberg M; Grunberger G
Am J Hypertens; 1995 May; 8(5 Pt 1):445-53. PubMed ID: 7662219
[TBL] [Abstract][Full Text] [Related]
32. [Long-term effects of glipizide at the pancreatic and extra-pancreatic level in non-insulin dependent diabetics].
Sánchez MS; Ordóñez AJ; Villalba MT; de la Viña S; Nash RE; Serrano M
Rev Med Chil; 1984 Feb; 112(2):107-14. PubMed ID: 6377432
[No Abstract] [Full Text] [Related]
33. Insulin and sulphonylurea in the therapy of type 2 diabetes.
Sotaniemi EA; Vierimaa E; Huupponen R; Karvonen I; Vuoti MJ; Rytömaa K
Diabetes Res Clin Pract; 1990 Mar; 8(3):243-51. PubMed ID: 2111239
[TBL] [Abstract][Full Text] [Related]
34. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
35. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of glipizide.
Feinglos MN; Lebovitz HE
Am J Med; 1983 Nov; 75(5B):60-6. PubMed ID: 6369969
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic equivalence of once- and thrice-daily glipizide.
Wåhlin-Boll E; Groop L; Karhumaa S; Groop PH; Tötterman KJ; Melander A
Eur J Clin Pharmacol; 1986; 31(1):95-9. PubMed ID: 3536529
[TBL] [Abstract][Full Text] [Related]
38. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Del Prato S; Camisasca R; Wilson C; Fleck P
Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
[TBL] [Abstract][Full Text] [Related]
39. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
40. Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.
Feinglos MN; Thacker CR; Lobaugh B; DeAtkine DD; McNeill DB; English JS; Bursey DL
Diabetes Res Clin Pract; 1998 Mar; 39(3):193-9. PubMed ID: 9649951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
